The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

FRIDAY, Dec. 13, 2024 (HealthDay News) -- A “watch-and-wait” strategy might be the best option for some women with ...

Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen ...

Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen ...

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

ACTIVE monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), ...

Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Two studies suggest that early breast cancer patients can safely avoid specific surgeries, including lymph node removal, and ...